Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium ...Middle East

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium )

Also on site :

• Beloved brand ends controversial 50 cent fee on popular breakfast staple as it gets ahead of Waffle House
• Wimbledon: Naomi Osaka loses to Anastasia Pavlyuchenkova in the 3rd round
• Should You Expect USPS Mail Delivery on July 4th?